AnaptysBio Inc Stock News

The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.

AnaptysBio has a number of molecules in pipeline and in partnered programs, but it has a history of failures for one molecule. The company's cash position is good.

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co

AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology.

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune co

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i

Toward the end of trading Wednesday, the Dow traded down 0.45% to 28550.31 while the NASDAQ fell 0.75% to 11775.45. The S&P also fell, dropping 0.56% to 3,492.39. The U.S....

Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

* Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Compan

* Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis * Secondary analyses demonstrated NPS and blood eosinop

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical nee

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline AdvancementSAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing